Dynamics of the U.S. 2022 Infant Formula Shortage and Recovery as Measured by In-stock Rates, Sales, and Household Experiences

Since the infant formula shortage experienced in the U.S. in 2022, the U.S. Food and Drug Administration (FDA) and other U.S. government partners have been working to ensure and expand consumer access to infant formula products, while also ensuring that these products are safe and nutritionally adequate. The FDA, in tandem with its federal and state partners, continues to monitor the supply of these critical food products in the wake of the 2022 shortage for signals of potential disruptions or shortages. As part of these activities, we investigated the spatial and temporal dynamics of the U.S. 2022 infant formula shortage and recovery. To achieve this, we examined three data sources: (1) estimates of infant formula availability from retailers' online marketplaces, (2) sales of infant formula products, and (3) consumer survey responses regarding infant formula access. Infant formula availability dropped to its lowest value in May 2022 following a surge in infant formula sales. The recovery from the shortage was geographically varied, and this variation persisted for nearly one year. Sales of infant formula, by form and by brands, deviated from historical norms (2019-2021) for most of 2022. During a period of increasing in-stock rates, declining state-to-state variability, and normalizing infant formula sales, U.S. consumers reported less difficulty purchasing infant formula. Sales spikes in infant formula products typically preceded observable changes in estimated in-stock rates by approximately one week. Simultaneously monitoring all three of these data streams provided a more comprehensive description of the status and dynamics of the infant formula supply in the U.S. during the periods surrounding the 2022 shortage and recovery than only one of these data streams could provide. Ongoing monitoring can provide the FDA with a continuous assessment of the infant formula supply status from these multiple perspectives.

Authors

Institutions

Publication Details

Journal
Journal of Food Protection
Published
2026-03-03
DOI
https://doi.org/10.1016/j.jfp.2026.100743
Primary Topic
Breastfeeding Practices and Influences
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dynamics of the U.S. 2022 Infant Formula Shortage and Recovery as Measured by In-stock Rates, Sales, and Household Experiences

David Oryang, Gavin Fenske, Jane Van Doren, Régis Pouillot et al.
Journal of Food Protection
Breastfeeding Practices and Influences
article

Dynamics of the U.S. 2022 Infant Formula Shortage and Recovery as Measured by In-stock Rates, Sales, and Household Experiences

David Oryang, Gavin Fenske, Jane Van Doren, Régis Pouillot, Brad Brown
article en

Abstract

Since the infant formula shortage experienced in the U.S. in 2022, the U.S. Food and Drug Administration (FDA) and other U.S. government partners have been working to ensure and expand consumer access to infant formula products, while also ensuring that these products are safe and nutritionally adequate. The FDA, in tandem with its federal and state partners, continues to monitor the supply of these critical food products in the wake of the 2022 shortage for signals of potential disruptions or shortages. As part of these activities, we investigated the spatial and temporal dynamics of the U.S. 2022 infant formula shortage and recovery. To achieve this, we examined three data sources: (1) estimates of infant formula availability from retailers' online marketplaces, (2) sales of infant formula products, and (3) consumer survey responses regarding infant formula access. Infant formula availability dropped to its lowest value in May 2022 following a surge in infant formula sales. The recovery from the shortage was geographically varied, and this variation persisted for nearly one year. Sales of infant formula, by form and by brands, deviated from historical norms (2019-2021) for most of 2022. During a period of increasing in-stock rates, declining state-to-state variability, and normalizing infant formula sales, U.S. consumers reported less difficulty purchasing infant formula. Sales spikes in infant formula products typically preceded observable changes in estimated in-stock rates by approximately one week. Simultaneously monitoring all three of these data streams provided a more comprehensive description of the status and dynamics of the infant formula supply in the U.S. during the periods surrounding the 2022 shortage and recovery than only one of these data streams could provide. Ongoing monitoring can provide the FDA with a continuous assessment of the infant formula supply status from these multiple perspectives.

Journal of Food ProtectionVol. 89(5)
Center for Food Safety and Applied Nutrition (US), United States Food and Drug Administration (US), Food and Drug Administration (TH), Society for Imaging Informatics in Medicine (US)
Openalex Percentile: Top 36%
Breastfeeding Practices and Influences
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.